The Merck vaccine: The key to protecting farmers

Farmers are getting the first look at the Merck Vaccine, and the reaction to it is mixed.

The company announced on Tuesday that farmers who have purchased a Merck Pro-Aged™ vaccine for the next year will be eligible for an additional $5,000 for their coverage through the end of 2019.

The Pro-Age® vaccine is expected to help protect the country’s corn and soybean crops from the deadly coronavirus, which has killed more than 1,000 people and sickened more than 5,000.

Farmers get the vaccine in three doses, two for each year of the crop.

They can choose between two different doses, the Merk version, which is a three-dose regimen, and a four-dose, three-month regimen.

The other two vaccines, the Pro-Beside and Pro-Mate, are being tested in the U.S. as well.

The Merk vaccine will be available to farmers for the first time in 2019.

In a statement, the U,S.

Department of Agriculture said it has “reopened” its investigation into the safety of the Pro and Mates.

The agency also said it is reviewing the Pro Vaccine and will take appropriate steps to ensure farmers receive all of the vaccinations they need.

“The Pro vaccine, which protects against coronaviruses like C.D.C., is being evaluated by the National Institutes of Health (NIH) for safety and efficacy in humans and has been approved for use by FDA,” it said.

“The Pro Mate vaccine is also under review for safety in humans.”

Merck is a major player in the health care industry, providing vaccines for about 60 diseases.

The company is known for its vaccines for common respiratory conditions like influenza and polio.

The vaccine has a 90 percent success rate against C.d.C. and a 90-95 percent success in humans.

The Pro-aged vaccine is being tested for the second time.

Merck and the NIH did not immediately respond to a request for comment.

The Merck statement came after the Associated Press reported on Tuesday on a $1 billion settlement in which Merck agreed to pay $1.5 billion in back payments for false claims it made about its vaccine in the 1980s.

The AP report showed that Merck had falsely said in 1989 that the Pro vaccine would be effective against Cd.c. in humans only.

The AP said the claim was based on a study that did not prove the vaccine was effective in humans at all.

Merks initial settlement with the AP was $2.2 billion, but it has since been reduced to $1,742 million.

The deal was made after the AP’s investigation found that the company knew the vaccine had serious side effects.

The federal government and Merck reached a settlement in 2016 that also included $1 million in back pay.

The Justice Department said that $1 in back compensation is the equivalent of $8.5 million.